# A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate

> **NCT04909801** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 338 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Abatacept
- **DRUG:** Adalimumab
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT04909801
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-15
- **Primary completion:** 2023-06-14
- **Final completion:** 2027-09-01
- **Target enrollment:** 338 (ACTUAL)
- **Last updated:** 2025-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04909801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04909801, "A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04909801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*